- |
BioNTech". investors.
biontech.de. p. 130.
Retrieved 28
December 2020. Joe Miller,
Clive Cookson (16
December 2020). "FT
People of the Year:
BioNTech's...
- The Pfizer–
BioNTech COVID-19 vaccine, sold
under the
brand name Comirnaty, is an mRNA-based COVID-19
vaccine developed by the
German biotechnology company...
- at Bio
NTech's laboratories in Mainz, Germany, just days
after the SARS-Cov-2
genetic sequence was
first made public. In
September 2020,
BioNTech received...
- Pfizer–
BioNTech's BNT162b2 COVID-19
vaccine for
widespread use. On 11 December, the FDA gave
emergency use
authorization for the Pfizer–
BioNTech COVID-19...
-
delivery schedule for Pfizer-
BioNTech’s COVID-19 vaccine." By the end of September,
Canada will
receive the 40
million Pfizer-
BioNTech doses.
Major General Fortin...
-
Administration (FDA)
first granted emergency use
authorization to the Pfizer–
BioNTech vaccine on
December 10, 2020, and m****
vaccinations began four days later...
-
regulatory authority recognized by the
World Health Organization (WHO): Pfizer–
BioNTech, Oxford–AstraZeneca,
Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin...
- Bank to
address the
health and
economic impact of COVID-19. Meanwhile,
BioNTech and the
European Union are
collaborating to ****ess mRNA
vaccine production...
- On 25
January 2021, the TGA
provisionally approved the two-dose Pfizer–
BioNTech COVID-19 vaccine,
named COMIRNATY, for use
within Australia. The provisional...
-
company BioNTech,
which in 2020
developed the
first messenger RNA-based
vaccine approved for use
against COVID-19. Türeci has
served as
BioNTech's chief...
